chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Chills; Fever; This spontaneous case was reported by a consumer and describes the occurrence of CHILLS (Chills) and PYREXIA (Fever) in a 54-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 030L20A) for COVID-19 vaccination.     No Medical History information was reported.    On 16-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 16-Jan-2021, the patient experienced CHILLS (Chills) and PYREXIA (Fever). The patient was treated with IBUPROFEN (ADVIL [IBUPROFEN]) at an unspecified dose and frequency. At the time of the report, CHILLS (Chills) and PYREXIA (Fever) was resolving.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medication was reported.; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of these events, a causal relationship cannot be excluded.
fever 102F up to 104F lasting several days, treated with Motrin, seen in office on 02/26/2010, no other sign of illness noted
Right basal ganglia hemorrhagic stroke with severe left hemiparesis and left neglect.
PULSE RATE; HEADACHE(COMING AND GOING); NAUSEA; FEVER; This spontaneous report received from a patient concerned a 67 year old male. The patient's height, and weight were not reported. No past medical history or concurrent conditions were reported.The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 207821A, expiry: UNKNOWN) dose was not reported, administered on 03-JUL-2021 09:30 for prophylactic vaccination. No concomitant medications were reported. On 03-JUL-2021, the subject experienced pulse rate. On 03-JUL-2021, the subject experienced headache (coming and going). On 03-JUL-2021, the subject experienced nausea. On 03-JUL-2021, the subject experienced fever. Laboratory data included: Body temperature (NR: not provided) 101 F, Body temperature decrease (NR: not provided) 97.1 F, and Pulse rate (NR: not provided) not reported. Treatment medications (dates unspecified) included: paracetamol. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from fever on 03-JUL-2021, had not recovered from headache(coming and going), and the outcome of nausea and pulse rate was not reported. This report was non-serious.
feeling tingly on her fingers feet, hand.; the always feel cold; hot flashes; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from medical information team. The reporter is the patient.  A female patient received bnt162b2 (BNT162B2), administration date 12Mar2021 (Batch/Lot number: unknown) as dose 1, single for covid-19 immunisation. Relevant medical history included: "Menopause" (unspecified if ongoing), notes: She's already passed menopause. The patient's concomitant medications were not reported. The following information was reported: PARAESTHESIA (non-serious) with onset Mar2021, outcome "unknown", described as "feeling tingly on her fingers feet, hand."; FEELING COLD (non-serious) with onset Mar2021, outcome "unknown", described as "the always feel cold"; HOT FLUSH (non-serious) with onset Mar2021, outcome "unknown", described as "hot flashes". The event "feeling tingly on her fingers feet, hand." was evaluated at the physician office visit. Therapeutic measures were taken as a result of paraesthesia, feeling cold, hot flush. Additional information: The patient's age was reported as 58 (unit: unknown). Clinical course: 12 hours after the patient's first covid shot, patient started feeling tingly on her fingers, feet, hand. It was intermittent but worse on her feet, and the always feel cold. The patient went to see her health care professional (reported as HCP) who told her she didn't know what to do. The patient was prescribed a steroid pack that she finished but it did not help. She's already passed menopause but has also been experiencing hot flashes like 5 times a day. The patient was querying if she needed to take the second dose because she was concerned about a reaction and querying if the second shot has the same ingredients with the first.   No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
10min p/vax became very pale, c/o nausea & blurred vision;BP 90/30, HR 60;rested for 10min & said felt fine BP 80/54;
Zoster with rash along (R) leg on 5/28/15. Treated with acyclovir.
At about 3 AM on 2/21/2023, I woke up with chills and a headache. I went back to sleep. I woke back up at about 6 AM, with a stronger headache, stronger chills, and a runny nose. I took three home antigen tests that morning, and they all yielded positive results. I phoned my healthcare provider, and I was prescribed Paxlovid. I took the Paxlovid as prescribed, and the symptoms resolved pretty quickly. On 2/25/2023 or 2/26/2023, I felt well and tested negative. About three days afterwards, I developed a runny nose, a headache, and a little bit of tightness in the chest. I took another home antigen test and got a positive result. I had a telehealth visit with a doctor and was told I had a rebound, which he said happens to about 20-25% of cases. He told me that I would have to wait it out, and he informed me of the CDC protocols for isolation and masking. At the time of this writing, I still have hoarseness and some tightness in the chest. I also get winded more easily. I normally walk two to four miles a day, but since I've had COVID-19, I have been getting two to three miles a day. I'm also slower now than I was before. I would say that I am now about 95% better.
patient had tested positive for Covid virus, after being fully vaccinated; patient had tested positive for Covid virus, after being fully vaccinated; This is a spontaneous report from a contactable consumer via medical information team. This consumer reported similar events for 37 patients. This is 34 of 37 reports. This consumer reported for an 67-years-old male patient who received first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Solution for injection, Lot Number: EN5318, Expiry date was not reported), via an unspecified route of administration on 28Jan2021 as dose 1, single and second dose of bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Solution for injection, Lot Number: EL9266, Expiry date was not reported), via an unspecified route of administration on 23Feb2021 as dose 2, single for COVID-19 immunization. Medical history included ongoing diabetes mellitus. The patient concomitant medications were not reported. It was reported that patient had tested positive for Covid virus, after being fully vaccinated on 12Aug2021. The patient underwent lab tests and procedures which included body mass index was 33.9 on an unknown date and NAAT Covid test (sars-cov-2 test) was positive on 12Aug2021. The outcome of the events was unknown.; Sender's Comments: Linked Report(s) : US-PFIZER INC-202101075254 Same reporter/drug/AE, different patients;US-PFIZER INC-202101081376 similar report from same reporter
The patient experienced tingling and numbness in her fingers; The patient experienced severe pain in the arm; The patient experienced tingling and numbness in her fingers; This spontaneous report as received from a patient's husband refers to a 61 year old female patient. The patient's concurrent conditions, pertinent medical history and concomitant therapy were not reported.  On an unknown date, the patient was vaccinated with a dose of measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live(M-M-R II) (dose, lot#, expiration date, route and albumin status were not reported)  for prophylaxis.         On an unknown date, after receiving the vaccine, the patient experienced severe pain in the arm (pain in extremity ), tingling (paraesthesia) and numbness (hypoaesthesia) in her fingers.The patient visited the physician and was prescribed an unspecified steroid to treat the pain and numbness.  At the time of the report, the outcome of hypoaesthesia, paraesthesia and pain in extremity was reported as not resolved.        The relationship between hypoaesthesia, paraesthesia, pain in extremity and measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live(M-M-R II) was not reported.
soreness in left arm; This spontaneous case was reported by a patient and describes the occurrence of PAIN IN EXTREMITY (soreness in left arm) in a 54-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 017B21A) for COVID-19 vaccination.     No Medical History information was reported.    On 15-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 15-Apr-2021, the patient experienced PAIN IN EXTREMITY (soreness in left arm). The patient was treated with IBUPROFEN at an unspecified dose and frequency. On 17-Apr-2021, PAIN IN EXTREMITY (soreness in left arm) had resolved. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications were reported
Information has been received from a lawyer regarding a case in litigation concerning a male patient of unknown age. No information was received regarding the patient's past medical history, concurrent conditions, or concomitant medication. The patient's healthcare provider recommended, and/or prescribed ZOSTAVAX to the patient for its intended purpose of permanent prevention and protection against shingles and zoster-related conditions. On or about 07-OCT-2014, a pharmacist at a pharmacy administered the ZOSTAVAX (lot number, dosage and route of administration not provided) to the patient. On or about 03-OCT-2015, the patient was treated by a physician at a physician's office for shingles. The patient was diagnosed with shingles and/or other zoster-related injuries after and despite being inoculated with the ZOSTAVAX vaccine, and suffered serious physical, emotional, and economic damages as a result of the patient's injuries. As a direct and proximate result of the ZOSTAVAX vaccine, the patient has and will continue to suffer ongoing injuries, including but not limited to: mental and physical pain and suffering; extensive medical care and treatment for these injuries; significant medical and related expenses as a result of these injuries, including but not limited to medical losses and costs including care for hospitalization, physician care, monitoring, treatment, medications, and supplies; diminished capacity for the enjoyment of life; a diminished quality of life; increased risk of premature death; aggravation of preexisting conditions and activation of latent conditions (unspecified); lost wages; loss of earnings capacity; and other losses and damages. The outcome of the events was considered to be not recovered. Causality assessment considered events to be related to the use of ZOSTAVAX. Additional information has been requested.
low grade fever, 99-101.1, 6 days p/vax; hospitalized; was not able to walk for a period of time; extremely high sedimentation rate; 5 MD are examining the blood studies; Can not find an etiology;
Red swollen, warm to touch, itchy - told to cool compress, TYLENOL/MOTRIN for any discomfort, draw circle around. - To come to office ASAP if worse or exceeds lines. Pt was treated with series of antibiotics.
Vaccine was administered on 06-Apr-2022, stored in refrigerator on 25-Feb-2022 and was expired on 25-Mar-2022; Patient was administered with vaccine which was expired on 25-Mar-2022 and past the 30 day storage on the refrigerator; This spontaneous case was reported by a nurse and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Patient was administered with vaccine which was expired on 25-Mar-2022 and past the 30 day storage on the refrigerator) and PRODUCT STORAGE ERROR (Vaccine was administered on 06-Apr-2022, stored in refrigerator on 25-Feb-2022 and was expired on 25-Mar-2022) in a 61-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 027L21A) for COVID-19 vaccination.     Concurrent medical conditions included Drug allergy (Hydrochlorothiazide allergy), Drug allergy (Lisinopril allergy), Latex allergy and Drug allergy. Concomitant products included FLUTICASONE FUROATE (ARNUITY ELLIPTA), CYCLOBENZAPRINE, GABAPENTIN, EPINEPHRINE (EPIPEN), MOMETASONE FUROATE (NASONEX), SALBUTAMOL (VENTOLIN [SALBUTAMOL]), DIAZEPAM (DELICA), ASCORBIC ACID, FERROUS FUMARATE (VITRON C [ASCORBIC ACID;FERROUS FUMARATE]), IBUPROFEN, ALLOPURINOL, LOSARTAN, GLIPIZIDE, LEVOCETIRIZINE, CARVEDILOL, FUROSEMIDE, AMLODIPINE BESYLATE and TRIAMCINOLONE ACETONIDE for an unknown indication.    On 06-Apr-2022, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 06-Apr-2022, the patient experienced EXPIRED PRODUCT ADMINISTERED (Patient was administered with vaccine which was expired on 25-Mar-2022 and past the 30 day storage on the refrigerator). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (Vaccine was administered on 06-Apr-2022, stored in refrigerator on 25-Feb-2022 and was expired on 25-Mar-2022). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Patient was administered with vaccine which was expired on 25-Mar-2022 and past the 30 day storage on the refrigerator) and PRODUCT STORAGE ERROR (Vaccine was administered on 06-Apr-2022, stored in refrigerator on 25-Feb-2022 and was expired on 25-Mar-2022) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   The patient took one touch verio as concomitant medication.  The patient received vaccine which was refrigerated on 25-Feb-2022 and was administered on 06-Apr-2022 after the expiration date of 25-Mar-2022. The vial did not undergo any temperature excursions. Patient did not experience any side effects at the time reporting. Patient have not experienced COVID-19 within last month.   No treatment information was provided.
Developed a fever of 104.5 on 10/29, which dropped to 102 with TYLENOL on board. Patient was extremely irritable, was not eating well and had less wet diapers. Patient continued having fevers until 10/31. Patients ears and urine were examined for possible infection but were WNL. No other symptoms.
pt called and said that the vaccine caused a staph infection.  she did get treatment from a doctor.  when I saw the site it was red, not raised and receding from the pen outline that the doctor had drawn on her arm. this was before she received any medications from our pharmacy.
body aches,  headache, stomach pain, chills & fever ( 104.5) fatigue.  Took 1000mg Tylenol every 6 hours , was careful not to exceed 4000mg in 24hrs. Drank cold fluids, stayed in bed for 3 days. Fever would decrease with tylenol down to 99 and then go right back up. After 3rd day, fever stayed down around 99-100.0 for another 2days. All symptoms gone at 5 days however still done feel "normal",  not my normal energy and tire very easily
Redness initially then by 10/25/13 left upper arm swelling erythema, and warmth extending from axillae area to elbow.
This spontaneous case was reported by a consumer and describes the occurrence of MALAISE (Felt very sick), VOMITING (I had vomiting) and PYREXIA (Fever) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. No Medical History information was reported.On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced MALAISE (Felt very sick), VOMITING (I had vomiting) and PYREXIA (Fever). At the time of the report, MALAISE (Felt very sick), VOMITING (I had vomiting) and PYREXIA (Fever) outcome was unknown. No  Concomitant medications were provided. No Treatment medications were provided. Reporter did not allow further contact
The patient passed out completely while sitting after having her 1st covid vaccine.  She was alert shortly thereafter but had blurry vision and low blood pressure.  She said she was very hot and was sweating somewhat.  We gave her some water and gradually she started feeling better.  In the meantime, we had call 911 and when they evaluated her, they felt it was somewhat of a panic attack since she did have anxiety before getting the vaccine.
rash; immense pains; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) for a Pfizer sponsored program (005570). The reporter is the patient.  A patient (no qualifiers provided) received bnt162b2 (BNT162B2), administration date 2021 (Batch/Lot number: unknown) as dose number unknown, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: RASH (non-serious) with onset 2021, outcome "not recovered", described as "rash"; PAIN (non-serious) with onset 2021, outcome "not recovered", described as "immense pains".  Additional information: The COVID vaccine had immense side effect to the patient's health humanity since last year the patient had been in talks to send letters to the office.  The lot number for bnt162b2 was not provided and will be requested during follow up.
My son stopped cooing and babbling after his vaccine. My son did not develop any new skills from date of vaccine to 8.5 months. His speech and motor skills that were developed regressed. (among other adverse reactions not limited to fever, prolonged crying for 7 days, rash).
Client came in with appointment from our state vaccine portal for his 1st Pfizer vaccination.  He completed a prevaccinatin checklist stating he had not had any other covid vaccine.  He was asked prior to vaccination as well.  He was made aware that he was getting the pfizer covid vaccine and was given Pfizer covid vaccine factsheet.   Vaccine administered.  Nurse, while reviewing in state registry, noted he had had 2 Moderna Vaccinations on 2/23/21 and 3/24/21.  Client states he doesn't remember getting those but did get a Shingrix shot so maybe that was they were.  No adverse reaction noted during time a clinic.  Client stated he would call his PCP.  He was encouraged to call his physician with any medical concerns or go to ER if symptoms warranted. Client verbalized understanding and agreement.
This patient has been receiving i.v. Immune globulin infusions monthly since 05/09/2019 without any adverse effects until 01/05/2023, when she developed an acute urticaria reaction while receiving her infusion of immune globulin. She's had this reaction with all subsequent infusions. Of interest is that the hives always begin at the left deltoid, the location of all four of her COVID-19 immunizations, and then travel down that arm. They occur about 30 minutes after the start of the infusion, always on the left deltoid and arm, regardless of which arm is infused.The next day, and subsequent days the pruritic hives are also noted at the scalp hairline and in the axillae and inframammary areas. They respond to oral corticosteroids, but not to oral antihistamines. They have occurred with both Gammagard and with Privigen brands of immune globulin.
Spreading redness, warm to touch, pain. Oral BENADRYL, ice packs PRN.
Vaccine given not approved for current age. "There was no adverse event that occured. There were n symptoms and therefore there was no treatment necessary."
This  68  year old   white  female received the Covid shot on  3/3/21 and went to the ED on 3/22/21 and was admitted  on  3/22/21 with  shortness of breath, pneumonia and died on 4/10/21 .  Please refer to the other details submitted within this report and contact the person who submitted this report via email for additional follow up details and investigation.
This spontaneous case was reported by a consumer and describes the occurrence of EMOTIONAL DISTRESS (Emotional distress), COVID-19 (COVID-19), FUNGAL INFECTION (Yeast infection) and VACCINATION FAILURE (Vaccination failure) in a 74-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. Co-suspect product included non-company product ADALIMUMAB (HUMIRA) for Panuveitis. Patient had no known allergies. No Medical History information was reported.  On 24-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 25-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 03-Mar-2022, the patient started ADALIMUMAB (HUMIRA) (Subcutaneous) Citrate free. In June 2022, the patient experienced COVID-19 (COVID-19) and VACCINATION FAILURE (Vaccination failure). In 2022, the patient experienced EMOTIONAL DISTRESS (Emotional distress) and FUNGAL INFECTION (Yeast infection). At the time of the report, EMOTIONAL DISTRESS (Emotional distress), COVID-19 (COVID-19), FUNGAL INFECTION (Yeast infection) and VACCINATION FAILURE (Vaccination failure) outcome was unknown. Concomitant medications were not provided by the reporter. Humira was taken for Non-infectious intermediate, Posterior and Panuveitis. It was unknown if patient was enrolled in a COVID-19 Vaccine Trial. Treatment information was not provided. Company Comment: This spontaneous case concerns a 74-year-old female patient with no relevant medical history reported, who experienced the unexpected non-serious of COVID-19 which occurred approximately 14 months after the second dose of mRNA-1273 vaccine. Additionally, vaccination failure is also noted in this case. No further details on clinical course, other lab test results and treatment received were reported. The outcome of the event was reported as unknown. Current pandemic situation of COVID-19 may remain as confounder to the event Covid-19. The benefit-risk relationship of mRNA-1273 Vaccine is not affected by this report.; Sender's Comments: This spontaneous case concerns a 74-year-old female patient with no relevant medical history reported, who experienced the unexpected non-serious of COVID-19 which occurred approximately 14 months after the second dose of mRNA-1273 vaccine. Additionally, vaccination failure is also noted in this case. No further details on clinical course, other lab test results and treatment received were reported. The outcome of the event was reported as unknown. Current pandemic situation of COVID-19 may remain as confounder to the event Covid-19. The benefit-risk relationship of mRNA-1273 Vaccine is not affected by this report.
Dead; Initial information received on 27-Jan-2022 regarding an unsolicited valid Social Media serious case received from a consumer/non-healthcare professional.  This case involves a 15 years old and unknown gender patient who was reported dead after receiving vaccine INFLUENZA VACCINE.  The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.  On an unknown date, the patient received a  dose of suspect INFLUENZA VACCINE produced by unknown manufacturer lot number not reported via unknown route in unknown administration site.  On an unknown date the patient was reported to be dead (death) (unknown latency) following the administration of INFLUENZA VACCINE. This event was assessed as medically significant and was leading to death.  Final diagnosis was (fatal) dead.  Action taken was not applicable.  It was not reported if the patient received a corrective treatment for the event (Dead).  At time of reporting, the outcome was Fatal for the event dead. No autopsy was done. The cause of death was reported as Unknown cause of death.; Reported Cause(s) of Death: Not Provided